Is Danaher's $10 Billion Bid for Masimo a Strategic Masterstroke or a Costly Diversion

Related Articles

Is Uber's €10 Billion Bid for Delivery Hero a Strategic Masterstroke or a Valuation Mismatch

4 months ago

Is Topicus.com's Revised ReadyTech Bid a Strategic Masterstroke

4 months ago

Is GM's ICE Investment a Retreat or a Strategic Masterstroke

7 months ago

Solstice's $14.5 Billion AI Bet: A Strategic Coup or a Costly Misstep?

3 months ago

Category

You may also like

Stock News•1 week ago

Eastover Investment Advisors LLC Makes New $1.15 Million Investment in Danaher Corporation $DHR

Eastover Investment Advisors bought a new 5,185-share stake in Danaher (NYSE: DHR) worth ~$1.15M in Q3, per its latest 13F filing. The position is a fresh institutional allocation, with other hedge fu...

DHR

Share

Stock News•1 week ago

GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition

GE HealthCare agreed to acquire radiopharmaceutical company Sofie Biosciences for $945M, expanding into the fast-growing radiopharmaceutical therapeutics market. The deal adds a new revenue stream in ...

GEHC

Share

Stock News•2 months ago

Masimo Appoints Tim Benner as President

Masimo appointed Tim Benner as president, effective immediately, as the Danaher-owned diagnostics firm reshapes leadership to drive its patient monitoring strategy.

Share